A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Enrollment
- 100
- Locations
- 10
- Primary Endpoint
- Estimated Glomerular Filtration Rate (eGFR)
Study Overview
Brief Summary
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female aged > 18 years of age at the time of consent.
- •Genetically confirmed diagnosis of Fabry disease.
- •Either taking or planning to take pegunigalsidase alfa as treatment for Fabry disease.
- •No contraindications for cardiac magnetic resonance imaging (cMRI)
- •Informed consent form (ICF) signed and dated indicating the individual has been informed of and agreed to all pertinent aspects of the study and is willing to comply with all study requirements, including completion of electronic patient reported outcomes (ePROs).
- •Cardiac Cohort:
- •Evidence of Fabry disease (FD)-related heart disease including one or more of the following:
- •Left ventricular hypertrophy (LVH) measured by left ventricular mass index (LVMI) (g/m2) elevation above age/sex specific reference ranges.
- •Posterior septum wall thickness (e.g., >=13mm) not explained by other factors (e.g., hypertension)
- •Low native T1 mapping on cMRI.
- •Typical Fabry-like scar on cMRI
- •Participants can receive cardiac magnetic resonance imaging (cMRI) with gadolinium enhancement as part of their SoC.
- •Estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m2, assessed within the prior 6 months.
- •Naïve Cohort:
- •Most recent eGFR>45 mL/min/1.73 m2, assessed within prior 6 months.
- •Male participants should have abnormal elevation in plasma lysoGb3 as assessed within 6 months prior to enrolment.
- •Long-Term Cohort:
- •Participants previously enrolled in the open label study CLI-06657AA1-04 (Previously PB-102-F60) (using pegunigalsidase alfa at a dose of 1mg/kg every 2 weeks) who have initiated or plan to initiate commercial pegunigalsidase alfa (Elfabrio®).
Exclusion Criteria
- •Contraindication to magnetic resonance imaging (MRI) including known history of hypersensitivity to gadolinium contrast agent that is not managed by the use of premedication.
- •Pregnant at the time of enrolment.
- •Presence of any medical, emotional, behavioural, or psychological condition that, in the judgment of the physician, could interfere with the ability to participate in the study.
- •Active participation in any interventional study for Fabry disease
- •Treatment regimen at the time of enrolment in the study is different from the approved 1mg/kg every two weeks (note if regimen subsequently changes during the prospective part of the study, the participants can remain in the study)
- •Prior participation in a pegunigalsidase alfa trial using a dose of 2 mg/kg administered every 4 weeks.
- •Cardiac Cohort:
- •History of acute myocardial infarction or congestive heart failure with reduced left ventricular (LV) ejection fraction of less than 35%.
- •Cerebral vascular accident (CVA) in the prior 6 months.
- •Chronic liver cirrhosis.
- •FD-unrelated heart disease (e.g., scarring due to myocardial infarction, symptomatic occlusive coronary artery disease, moderate valvular heart disease not thought to be Fabry related).
- •The participant is or has been treated with any investigational drug for Fabry disease within 6 months of study start or investigational gene therapy for Fabry disease at any time point in the past.
- •Severe cardiac fibrosis defined as more than 3 segments that each have >50% fibrosis upon late gadolinium enhancement cMRI at any prior cMRI.
- •Naïve Cohort:
- •Prior exposure to a FD therapy (Replagal®, Fabrazyme®, and Galafold®) at any time point.
- •Severe cardiac fibrosis defined as more than 3 segments that each have >50% fibrosis upon late gadolinium enhancement cMRI on any prior cMRI
Arms & Interventions
Cardiac Cohort
Patients with Fabry-related cardiac disease
Intervention: Pegunigalsidase-alfa (Drug)
Naïve Cohort
Patients naïve to prior Fabry disease treatment
Intervention: Pegunigalsidase-alfa (Drug)
Long-Term Cohort
Patients previously participating in the pegunigalsidase alfa open label extension study and transitioning to routine care
Intervention: Pegunigalsidase-alfa (Drug)
Outcomes
Primary Outcomes
Estimated Glomerular Filtration Rate (eGFR)
Time Frame: 4 years
eGFR, calculated using the Chronic Kidney Disease - Epidemiology Collaboration (eGFRCKD-EPI) equation from study baseline and from pegunigalsidase alfa treatment start to end of follow-up and to pre-specified time points (annually).
Plasma Globotriaosylsphingosine (LysoGb3) Concentration
Time Frame: 4 years
Levels of the Fabry disease biomarker plasma globotriaosylsphingosine (lyso-Gb3) over time, and change from study baseline and from pegunigalsidase alfa treatment start to end of follow-up.
Left Ventricular Mass Index (LVMI; g/m2)
Time Frame: 4 years
Change in LVMI over time as assessed by cardiac MRI. Based on LVM indexed by height and/or body surface area.
High Sensitivity Troponin (hs-cTnT)
Time Frame: 4 years
Change in levels of hs-cTnT over time
Safety Assessments
Time Frame: 4 years
The endpoints will include occurrence of SAEs, infusion-related reactions (IRRs), drug-related adverse events, and proportion of participants with ADAs over time.
Secondary Outcomes
No secondary outcomes reported